Navigation Links
National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)

WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ -- The non-profit National Patient Advocate Foundation (NPAF), representing the voice of millions of patients assisted nationally in more than a decade through our direct-patient-services affiliate Patient Advocate Foundation (PAF), continues to routinely receive inquiries from patients wanting to know more about the use of Erythropoietin Stimulating Agents (ESA). These patients, with life-threatening, debilitating and chronic conditions, continue to seek information about best-available treatment and payment options from PAF - and we share their concerns and frustrations about the lack of information available on the safe use of ESAs.

We commend the FDA and ESA sponsors for their diligence, especially in recent months, to garner the information that patients and their physicians need to make the best informed decisions about the use of these important therapies.

NPAF believes that both the sponsors and the FDA have the responsibility to demonstrate to the American public that ESA drugs are safe and effective when administered within the recommended guidelines. Despite known and long-term safety concerns about these drugs, so far the evidence needed to clear up the questions of safety remains lacking. Further scientific studies are currently underway, but may take from months to years to complete. NPAF intends to promote the necessary clinical trials, and will participate in a workshop at the National Cancer Institute next month to further define the additional studies needed for ESA drugs.

Due to the urgent need for updated information reaching the public on ESAs, NPAF strongly encourages the FDA and sponsors to create a Medication Guide on ESAs, as discussed recently by Dr. Richard Padzur, director of the FDA Division of Oncology Drug Products.

In summary, FDA has taken the unusual position of raising serious concerns about ESA drugs despite what seems to be a lack of definitive scientific proof based on the findings of six studies conducted in which ESA dosing levels were higher than the current label dosing indications. We commend that tough decision by FDA. Until better evidence on these treatments can be developed, we believe that patients and physicians are best served by adhering to the label restrictions FDA has now put in place on ESAs.

In the meantime, we encourage patients to visit to view the FDA Public Health Announcement, FDA Questions and Answers and the full text of the new FDA labels for the Epogen and Aranesp and to contact our specialized case managers via 1-800-532-5274 to learn more.

SOURCE National Patient Advocate Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Yakima Health Care Leader Tapped for Leadership Post at National Association
3. Virginia Tech Report Has National Importance
4. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
8. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. LCA Hails International Investigators Studying Lung Cancer
11. National Patient Safety Foundation Partners with Vocera Communications
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology: